This comprehensive review evaluates the clinical and technical landscape of dual-target mRNA vaccines—specifically Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030—designed to provide simultaneous protection against seasonal influenza and SARS-CoV-2. Both platforms utilize lipid nanoparticle (LNP) delivery systems to encode for viral antigens, including the SARS-CoV-2 spike protein and multiple influenza hemagglutinin (HA) strains. Comparative analysis of Phase III clinical trial data indicates that Moderna’s mRNA-1083 demonstrated superior immunogenicity, meeting non-inferiority and superiority criteria for multiple influenza strains and the Omicron variant. In contrast, while Pfizer’s candidate showed robust responses to Influenza A and COVID-19, it failed to meet non-inferiority benchmarks for Influenza B. The review highlights that combination vaccines significantly enhance public health efficiency by improving patient compliance and simplifying immunization logistics, though challenges regarding global vaccine equity and the rapid mutation rates of the target viruses remain.
Comparative Analysis of Dual-Target mRNA Vaccine Candidates
Public Health Rationale: Influenza and COVID-19 co-circulation presents high mortality risks, particularly in Southeast Asia and sub-Saharan Africa. Prior influenza A infection is shown to promote SARS-CoV-2 entry, necessitating combined immunization strategies to curb co-infection complications.
Technological Foundation: Both manufacturers utilize modified nucleoside mRNA encapsulated in lipid nanoparticles (LNPs). Moderna historically employs higher mRNA dosages (e.g., 100 µg vs. Pfizer’s 30 µg), which may correlate with more robust initial immune responses and enhanced thermal stability for easier distribution.
Moderna mRNA-1083 Profile: A bivalent candidate combining mRNA-1010 (quadrivalent flu) and mRNA-1283 (next-generation COVID-19). Phase III trials involving ~8,000 adults showed significantly higher immune responses against H1N1, H3N2, B/Victoria, and the Omicron XBB.1.5 variant compared to co-administered licensed vaccines (Fluzone HD and Spikevax).
Pfizer/BioNTech mRNA-1020/1030 Profile: This candidate integrates an Omicron-adapted (BA.4/BA.5) COVID-19 component with a quadrivalent influenza component. While Phase III data demonstrated robust Influenza A and SARS-CoV-2 neutralization, the formulation failed to meet non-inferiority criteria for the Influenza B strain, prompting ongoing modifications.
Safety and Reactogenicity: Both candidates report primarily Grade 1 and Grade 2 adverse events, such as injection site pain, fatigue, and headache. However, Pfizer’s broader post-marketing data (outside this specific trial) has noted rare severe reactions like anaphylaxis, whereas Moderna’s mRNA-1083 trial reported no severe adverse events.
Impact on Vaccine Uptake: Studies suggest COVID-19 booster uptake may increase by over 56% when combined with a seasonal influenza shot. This "single-visit" approach addresses "booster fatigue" and reduces healthcare infrastructure burdens.
Global Equity Concerns: The high production cost and technical requirements for mRNA/LNP platforms risk exacerbating health disparities. Experts emphasize the need for technology transfer and subsidization to ensure low- and middle-income countries (LMICs) can access these combined therapies.
Future Directions: The modularity of the mRNA platform allows for rapid "plug-and-play" updates to match circulating strains. Future iterations (e.g., Moderna’s mRNA-1230) aim to integrate Respiratory Syncytial Virus (RSV) protection into a single "respiratory combination" vaccine.
Study Limitations: Current conclusions are based on preliminary data from publicly available manufacturer announcements; finalized dosing schedules and long-term peer-reviewed safety data for the specific combination formulations are still pending Phase III completion.